DOCSLIB.ORG

MS-Based Targeted Metabolomics of Eicosanoids

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

MS-based targeted metabolomics of eicosanoids and other oxylipins: Analytical variability and interlaboratory comparison of esterified oxylipin profile Céline Dalle, Malwina Mainka, Jessica Dalloux-Chioccioli, Annika I Ostermann, Michael Rothe, John W. Newman, Cécile Gladine, Nils Helge Schebb To cite this version: Céline Dalle, Malwina Mainka, Jessica Dalloux-Chioccioli, Annika I Ostermann, Michael Rothe, et al.. MS-based targeted metabolomics of eicosanoids and other oxylipins: Analytical variability and interlaboratory comparison of esterified oxylipin profile. European RFMF Metabomeeting 2020, Jan 2020, Toulouse, France. 262 p., 2020, Oral and Poster Abstracts European RMF Metabomeeting 2020. hal-02494583 HAL Id: hal-02494583 https://hal.archives-ouvertes.fr/hal-02494583 Submitted on 2 Jun 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Distributed under a Creative Commons Attribution| 4.0 International License [Tapez ici] [Tapez- 0 - ici] [Tapez ici] We are very pleased to welcome you to the 2020 European RFMF-Metabomeeting conference in Toulouse. This conference gathers together two metabolomics and fluxomics networks, the RFMF (French- speaking Metabolomics and Fluxomics Network) and the MPF (Metabolic Profiling Forum) with more than 10 years of existence. MPF and RFMF share the same objectives which are to catalyze metabolomics and fluxomics research, organize conferences and promote early career scientists. Both networks also put forward networking and social aspects as strong leverage to achieve cutting edge science. For all these reasons we decided to organize this joint event. With the growing interest in metabolomics, several regional and national networks have been created across Europe (and affiliated islands) within the last years. That is the reason why we decided to also include them in the organization of this event. They were particularly instrumental in creating a high-level scientific program and providing travel grants (a staggering 21 travel grants!). We expect this conference to demonstrate the recent breakthroughs in metabolomics and fluxomics in a wide range of application fields. We made the choice to keep the scope of the conference as broad as possible (in terms of techniques and applications) since we think that interactions between communities is key in creating new paradigms, collaborations and scientific hypothesis. One of our aims in this conference is to promote early career scientist participation. That is the reason why we did our best to keep registration prices as low as possible. As mentioned, networks made a strong effort to offer travel grants. Early careers were also strongly involved in the scientific organization of the conference. In fact, an early career committee was set up, led by Alison Woodward, and selected the early career presentations that you will see during the conference. They also proposed and organized workshops and social events. Finally, they will co-chair sessions with the (less early career) scientists. Good science is generally the outcome of hard work within a friendly and supportive environment. All organisers agreed on the fact that this friendly atmosphere is of upmost importance for the organization of the conference. That is the reason why we did our best to have exciting social and networking events before and during the conference. We also aim at following RFMF mantra of “Good food Good science” with a very local and original gala dinner. Finally, we would like to acknowledge all the academic and industrial sponsors for supporting this event and previous ones. We also thank all the people involved in the scientific and practical organization of this conference. MetaboHub-Metatoul metabolomics and fluxomics facility contribution was outstanding and our warmest thoughts go to Justine Bertrand Michel and Floriant Bellvert for their hard work and unbreakable optimism. We wish you a fruitful scientific, human and enjoyable conference! Jules Griffin (MPF) Fabien Jourdan (RFMF) - 1 - - 2 - - 3 - ACADEMIC PARTNERS - 4 - PLATINIUM SPONSORS - 5 - GOLD SPONSORS SILVER SPONSORS - 6 - BRONZE SPONSORS MEDIA SPONSORS - 7 - EUROPEAN REGIONAL AND NATIONAL NETWORKS AND SOCIETIES - 8 - - 9 - SCIENTIFIC COMMITTEE Floriant Bellvert RFMF CNRS Justine Bertrand RFMF INSERM Michel Lorraine Brennan Ireland University College Dublin The University of Karl Burgess Scottish Metabolomics Network Edinburgh Marta Cascante Spanish Metabolomics Society University Barecelona Frédérique Courant RFMF Université de Montpellier Pietro Franceschi Italian Metabolomics Network Fondazione Edmund Mach Patrick Giraudeau RFMF Université de Nantes Roy Goodacre MPF University of Liverpool Jules Griffin MPF Imperial College Robert Hall Netherlands Metabolomics Centre Wageningen University Anne-Emmanuelle Hay RFMF Université de Lyon 1 Fabien Jourdan RFMF INRA Christophe Junot RFMF CEA Dong-Hyun Kim MPF University of Nottingham Leibniz Institute for Plant Steffen Neumann German Society for Metabolomics Research Biochemistry MateJ Oresic Nordic Metabolomics Society Orebro University Jean-Charles Portais RFMF Université Paul Sabatier Serge Rudaz Swiss Metabolomics Society Université de Genève Andrew Southam MPF University of Birmingham Alison Woodward MPF University of Nottingham - 10 - EARLY CAREER SCIENTIFIC COMMITTEE Jordi Capellades Spanish Metabolomics Society Sylvain Dechaumet RFMF junior Yoric Gagnebin Swiss Metabolomics Society Kate Gallagher MPF Natasa Giallourou MPF Corentine Goossens RFMF junior Katharina Herzog Nordic Metabolomics Society Justine Leenders RFMF junior Youzhong Liu YoungNMC Clément Regnault Scottish Metabolomics Network Sara Tortorella Italian Metabolomics Network Alison Woodward MPF - 11 - LOCAL ORGANISING COMMITTEE Floriant Bellvert MetaboHub-Metatoul Cécilia Berges MetaboHub-Metatoul Justine Bertrand Michel MetaboHub-Metatoul Maxime Chazalviel MedDay Pharmaceuticals Frédérique Courant Université de Montpellier Sandrine Ellero-Simatos INRA-Toxalim Yoann Gloaguen Berlin Institute of Health Anne-Emmanuelle Hay Université de Lyon Fabien Jourdan MetaboHub-Metatoul Hanna Kulyk Barbier MetaboHub-Metatoul Loïc Mervant MetaboHub-Metatoul Jean-Charles Portais MetaboHub-Metatoul Pablo Rodriguez Mier INRA-Toxalim - 12 - - 13 - Workshop 1: W1 Meet the editor (January 21st 8:30pm-10pm) Purpose of the workshop: Attendees will meet editors and reviewers to discuss the following points: • Scientific inspiration versus literary perspiration: What makes a good (Metabolomics) paper? • What you should never do in papers. • Refereeing process: what happens once I have submitted my paper to the abyss... • Scientific ethics: objectivity versus subjectivity Skills acquired at the end of the workshop: • A general understanding of the publication process. • How to be a good reviewer and how to respond to reviewers (good and bad!) • Some further ideas to make your paper better. Intended audience and prerequisites: • Public: priority to early career but can go beyond • Prerequisites: did publish or plan to Organisers: Katharina Herzog, Kate Gallagher, Natasa Giallourou, Roy Goodacre and Jules Griffin. - 14 - Workshop 2: W2 Interactive tutorial, How to process LC-MS data with workflow4metabolomics.org (January 21st, 9am-12am) Purpose of the workshop: Metabolomics data analysis is a complex, multistep process, which is constantly evolving with the development of new analytical technologies, mathematical methods, and bioinformatics tools and databases. The Workflow4Metabolomics(W4M) project aims at developing full LC/MS,GC/MS,FIA/MS and NMR pipelines using Galaxy framework for data analysis including preprocessing, normalization, quality control, statistical analysis and annotation steps. https://workflow4metabolomics.org Intended audience and prerequisites: • Public: Researchers or students involved in metabolomics by LC-MS • Prerequisites: basic knowledge’s of the usual data processing steps for LC-MS metabolomics Skills acquired at the end of the workshop: • What is Galaxy? • Comprehend the diversity of LC-MS metabolomic data analysis. • Get familiar with the main steps constituting a metabolomic workflow for untargeted LC-MS analysis. • Evaluate the potential of a workflow approach when dealing with LC-MS metabolomic data. Organisers: Franck Giacomoni, Yann Guitton and Marie Tremblay Franco References: https://workflow4metabolomics.org Guitton et al (2017) Create, run, share, publish, and reference your LC–MS, FIA–MS, GC–MS, and NMR data analysis workflows with the Workflow4Metabolomics 3.0 Galaxy online - 15 - Workshop 3: W3 metaRbolomics hackathon plus (January 21st 2020, 1pm-3:45pm.) Purpose of the workshop: The idea of this hackathon is to have a quiet space where active developers and advanced users can work on integrating their packages in R, adding new data to wikidata or wikipathways, mapping identifiers with BridgeDb, tailor-making MetFrag databases to answer identification questions. The hackathon will start with Jo Rainer presenting the new R packages at https://RforMassSpectrometry.org and
Recommended publications
  • S41598-018-25035-1.Pdf

    S41598-018-25035-1.Pdf

    www.nature.com/scientificreports OPEN An Innovative Approach for The Integration of Proteomics and Metabolomics Data In Severe Received: 23 October 2017 Accepted: 9 April 2018 Septic Shock Patients Stratifed for Published: xx xx xxxx Mortality Alice Cambiaghi1, Ramón Díaz2, Julia Bauzá Martinez2, Antonia Odena2, Laura Brunelli3, Pietro Caironi4,5, Serge Masson3, Giuseppe Baselli1, Giuseppe Ristagno 3, Luciano Gattinoni6, Eliandre de Oliveira2, Roberta Pastorelli3 & Manuela Ferrario 1 In this work, we examined plasma metabolome, proteome and clinical features in patients with severe septic shock enrolled in the multicenter ALBIOS study. The objective was to identify changes in the levels of metabolites involved in septic shock progression and to integrate this information with the variation occurring in proteins and clinical data. Mass spectrometry-based targeted metabolomics and untargeted proteomics allowed us to quantify absolute metabolites concentration and relative proteins abundance. We computed the ratio D7/D1 to take into account their variation from day 1 (D1) to day 7 (D7) after shock diagnosis. Patients were divided into two groups according to 28-day mortality. Three diferent elastic net logistic regression models were built: one on metabolites only, one on metabolites and proteins and one to integrate metabolomics and proteomics data with clinical parameters. Linear discriminant analysis and Partial least squares Discriminant Analysis were also implemented. All the obtained models correctly classifed the observations in the testing set. By looking at the variable importance (VIP) and the selected features, the integration of metabolomics with proteomics data showed the importance of circulating lipids and coagulation cascade in septic shock progression, thus capturing a further layer of biological information complementary to metabolomics information.
  • A Metabolomics Approach to Pharmacotherapy Personalization

    A Metabolomics Approach to Pharmacotherapy Personalization

    Journal of Personalized Medicine Review A Metabolomics Approach to Pharmacotherapy Personalization Elena E. Balashova *, Dmitry L. Maslov and Petr G. Lokhov Institute of Biomedical Chemistry, Pogodinskaya St. 10, Moscow 119121, Russia; [email protected] (D.L.M.); [email protected] (P.G.L.) * Correspondence: [email protected] Received: 29 June 2018; Accepted: 3 September 2018; Published: 5 September 2018 Abstract: The optimization of drug therapy according to the personal characteristics of patients is a perspective direction in modern medicine. One of the possible ways to achieve such personalization is through the application of “omics” technologies, including current, promising metabolomics methods. This review demonstrates that the analysis of pre-dose metabolite biofluid profiles allows clinicians to predict the effectiveness of a selected drug treatment for a given individual. In the review, it is also shown that the monitoring of post-dose metabolite profiles could allow clinicians to evaluate drug efficiency, the reaction of the host to the treatment, and the outcome of the therapy. A comparative description of pharmacotherapy personalization (pharmacogenomics, pharmacoproteomics, and therapeutic drug monitoring) and personalization based on the analysis of metabolite profiles for biofluids (pharmacometabolomics) is also provided. Keywords: pharmacometabolomics; metabolomics; pharmacogenomics; therapeutic drug monitoring; personalized medicine; mass spectrometry 1. Introduction The uniformity of the drug response or low inter-individual differences in drug response are commonly accepted tenets in the field of medicine. Almost all drugs are prescribed on the basis of this statement. This approach can be described as treatment of the “average patient” by “the average pill” or “one size fits all”. However, clinicians have long observed that the actual effectiveness of the pharmacotherapy may be variable.
  • The Metabolomic Paradigm of Pharmacogenomics in Complex

    The Metabolomic Paradigm of Pharmacogenomics in Complex

    ics: O om pe ol n b A a c t c e e M s s Cacabelos, Metabolomics 2012, 2:5 Metabolomics: Open Access DOI: 10.4172/2153-0769.1000e119 ISSN: 2153-0769 Editorial Open Access The Metabolomic Paradigm of Pharmacogenomics in Complex Disorders Ramón Cacabelos1,2* 1EuroEspes Biomedical Research Center, Institute for CNS Disorders and Genomic Medicine, EuroEspes Chair of Biotechnology and Genomics, 15165-Bergondo, Corunna, Spain 2President, World Association of Genomic Medicine, Spain Metabolomics represents the networking organization of multiple pathogenic genes usually converge in metabolomic networks leading biochemical pathways leading to a physiological function in living to specific pathogenic cascades responsible for disease phenotypes. organisms. The frontier between health and disease is likely to be the The genomics of the mechanism of action of drugs has so far been result of a fine-tuning equilibrium or disequilibrium, respectively, neglected by the scientific community, and consequently less than 5% between the genomic-transcriptomic-proteomic-metabolomic cascade of FDA-approved drugs, with a pharmacologically-defined mechanism and environmental factors and/or epigenetic phenomena. In recent of action, have been studied in order to evaluate whether mutations times, diverse metabolomic studies have emerged in medical science in the genes encoding receptors or enzymes may affect efficacy and to explain physiological and pathogenic events in several disciplines, safety issues. Pleiotropic genes, involved in multiple pathogenic events,
  • Model-Based Integration of Genomics and Metabolomics Reveals SNP Functionality in Mycobacterium Tuberculosis

    Model-Based Integration of Genomics and Metabolomics Reveals SNP Functionality in Mycobacterium Tuberculosis

    Model-based integration of genomics and metabolomics reveals SNP functionality in Mycobacterium tuberculosis Ove Øyåsa,b,1, Sonia Borrellc,d,1, Andrej Traunerc,d,1, Michael Zimmermanne, Julia Feldmannc,d, Thomas Liphardta,b, Sebastien Gagneuxc,d, Jörg Stellinga,b, Uwe Sauere, and Mattia Zampierie,2 aDepartment of Biosystems Science and Engineering, ETH Zurich, 4058 Basel, Switzerland; bSIB Swiss Institute of Bioinformatics, 1015 Lausanne, Switzerland; cDepartment of Medical Parasitoloy and Infection Biology, Swiss Tropical and Public Health Institute, 4051 Basel, Switzerland; dUniversity of Basel, 4058 Basel, Switzerland; and eInstitute of Molecular Systems Biology, ETH Zurich, 8093 Zurich, Switzerland Edited by Ralph R. Isberg, Tufts University School of Medicine, Boston, MA, and approved March 2, 2020 (received for review September 12, 2019) Human tuberculosis is caused by members of the Mycobacterium infection of macrophages (29–32). Beyond analyses of individual tuberculosis complex (MTBC) that vary in virulence and transmis- laboratory strains, however, no systematic characterization and sibility. While genome-wide association studies have uncovered comparative analysis of intrinsic metabolic differences across several mutations conferring drug resistance, much less is known human-adapted MTBC clinical strains has been performed. about the factors underlying other bacterial phenotypes. Variation If the metabolic and other phenotypic diversity between in the outcome of tuberculosis infection and diseases has been MTBC strains contributes to and modulates pathogenicity, an attributed primarily to patient and environmental factors, but obvious question is: Which elements of the limited genetic di- recent evidence indicates an additional role for the genetic diver- versity in the MTBC are responsible for phenotypic strain di- sity among MTBC clinical strains.
  • M. Tomita T. Nishioka (Eds.) Metabolomics the Frontier of Systems Biology

    M. Tomita T. Nishioka (Eds.) Metabolomics the Frontier of Systems Biology

    M. Tomita T. Nishioka (Eds.) Metabolomics The Frontier of Systems Biology M. Tomita, T. Nishioka (Eds.) Metabolomics The Frontier of Systems Biology With 112 Figures, Including 4 in Color Springer Masaru Tomita, Ph.D. Professor and Director Institute for Advanced Biosciences Keio University Tsuruoka 997-0035, Japan Takaaki Nishioka, Ph.D. Professor Graduate School of Agricuhure Kyoto University Kyoto 606-8502, Japan This book is based on the Japanese original, M. Tomita, T. Nishioka (Eds.), Metabolome Kenkyu no Saizensen, Springer-Verlag Tokyo, 2003. Library of Congress Control Number: 2005928331 ISBN 4-431-25121-9 Springer-Verlag Tokyo Berlin Heidelberg New York This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in other ways, and storage in data banks. The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. Product liability: The publishers cannot guarantee the accuracy of any information about dosage and application contained in this book. In every individual case the user must check such information by consulting the relevant literature. Springer is a part of Springer Science+Business Media springeronline.com © Springer-Vertag Tokyo 2005 Printed in Japan Typesetting: Camera-ready by the editor. Printing and binding: Nikkei Printing, Japan Printed on acid-free paper Preface The aim of this book is to review metabolomics research.
  • Lipidomics and Metabolomics Service Gain Deeper Insights Into Exosomes

    Lipidomics and Metabolomics Service Gain Deeper Insights Into Exosomes

    EXOSOMES LIPIDOMICS AND METABOLOMICS SERVICE GAIN DEEPER INSIGHTS INTO EXOSOMES SYSTEMBIO.COM/LIPIDOMICS HIGHLIGHTS What can lipidomics of exosomes tell you? n Discover novel circulating biomarkers Lipids are an important part of cellular physiology, and are increasingly being recognized for their importance in exosome biology as well. Exosomes were recently shown to have the highest lipid- n Learn more about exosome biology to-protein ratio of all classes of extracellular vesicles (1), with lipid content that both differs from n Send us your sample and receive data the parent cell the vesicles are shed from (2) and also changes as exosomes undergo a variety of in 4 - 6 weeks physiological processes (3). These unique lipid profiles can serve as novel circulating biomarkers, and recent evidence suggests that specific lipid species carried by exosomes can also modulate Service Overview the function of recipient cells (4). Whether you’re interested in With so much information revealed by lipid content, lipidomics studies of exosomes are a great way to identify lipid-based biomarkers and for understanding vesicle biogenesis and function (5). circulating biomarker discovery, basic exosome research, or other TUMOR MICROENVIRONMENT exosome-related studies, SBI’s CANCER CELLS CAFs EXOSOMES Exosome Lipidomics & Metabolomics Service helps you quickly and efficiently get the most information from your exosomes. Simply send Exosomes affect metabolism of cancer us your sample or purified exosomes cells A recent study by Zhao, et al, (6) and we’ll send back a report with demonstrated that exosomes from putative identifications, mass/charge patient-derived cancer-associated fibroblasts (CAFs) can reprogram EXOSOME ratios, and differential analysis (if UPTAKE the cellular machinery in cancer requested).
  • IPA Analysis of Metabolomics Data Including Cross-Platform Integration with Transcriptomics Data from a Diabetic Mouse Model

    IPA Analysis of Metabolomics Data Including Cross-Platform Integration with Transcriptomics Data from a Diabetic Mouse Model

    IPA Analysis of Metabolomics Data Including Cross-Platform Integration with Transcriptomics Data from a Diabetic Mouse Model CONTENTS Overview ........................................................................................................................................................................ 3 Introduction ................................................................................................................................................................... 3 Metabolomics Background ........................................................................................................................................ 3 Integration of Metabolomic and Transcriptomic data .............................................................................................. 5 The Ingenuity Platform .............................................................................................................................................. 5 Case Study Background ............................................................................................................................................. 5 Methods ........................................................................................................................................................................ 6 Establishing a Metabolite profile for db/db mice and identification of exploratory biomarkers .............................. 6 IPA-Metabolomics™ Analysis: ...................................................................................................................................
  • Proteomics and Metabolomics: the Final Frontier of Nutrition Research 71

    Proteomics and Metabolomics: the Final Frontier of Nutrition Research 71

    SIGHT AND LIFE | VOL. 29(1) | 2015 PROTEOMICS AND METABOLOMICS: THE FINAL FRONTIER OF NUTRITION RESEARCH 71 Proteomics and Metabolomics: The Final Frontier of Nutrition Research Richard D Semba RNA editing, RNA splicing, post-translational modifications, and Wilmer Eye Institute, Johns Hopkins University School protein degradation; the proteome does not strictly reflect the of Medicine, Baltimore, Maryland, USA genome. Proteins function as enzymes, hormones, receptors, immune mediators, structure, transporters, and modulators of cell communication and signaling. The metabolome consists Introduction of amino acids, amines, peptides, sugars, oligonucleotides, ke- Revolutionary new technologies allow us to penetrate scientific tones, aldehydes, lipids, steroids, vitamins, and other molecules. frontiers and open vast new territories for discovery. In astrono- These metabolites reflect intrinsic chemical processes in cells my, the Hubble Space Telescope has facilitated an unprecedent- as well as environmental exposures such as diet and gut micro- ed view outwards, beyond our galaxy. Wherever the telescope is bial flora. The current Human Metabolome Database contains directed, scientists are making exciting new observations of the more than 40,000 entries7 – a number that is expected to grow deep universe. Another revolution is taking place in two fields quickly in the future. of “omics” research: proteomics and metabolomics. In contrast, The goals of proteomics include the detection of the diver- this view is directed inwards, towards the complexity of biologi- sity of proteins, their quantity, their isoforms, and the localiza- cal processes in living organisms. Proteomics is the study of the tion and interactions of proteins. The goals of metabolomics structure and function of proteins expressed by an organism.
  • ACE Human Metabolome Library Sub Title

    ACE Human Metabolome Library Sub Title

    TMIC The Metabolomics Innovation Centre www.metabolomicscentre.ca ACE Human Metabolome Library Sub title Aordable, Customizable and Extensive The ACE™ Human Metabolome Library (ACE™-HML) is a comprehensive library of standards representing a broad range of metabolites commonly found in human tissues. It is designed to assist researchers and service laboratories in the identication and quantication of compounds using a wide variety of analytical platforms with applications in medicine, toxicology, food and agriculture. In addition to typical products of primary human metabolism, the library includes an extensive repertoire of environmental contaminants, drug products and other chemical compounds. AFFORDABLE Starting from $25/metabolite Available individually or in groups ACE™-HML EXTENSIVE CUSTOMIZABLE 1,000+ metabolites High purity Assorted varieties Pre-weighed (10 mg/metabolite) TMIC is Canada’s national metabolomics facility, supporting a wide range of state-of-the-art metabolomics analysis for clinical trials research, biomedical studies, bio-products studies, nutrient profiling, and environmental testing. Features 1000+ metabolites available individually or in various combinations High-purity of >95% An assortment of packs representing specific metabolic pathways and compound types Pre-weighed (10 mg/metabolite) Affordable starting from$25/metabolite 77 Serum Metabolites 94 Drugs 221 Urine Metabolites ACE™-HML ACE™-HML 250 Water Contaminants 221 Disinfection By-products 90 Food 127 Components Organic Acids A complete list of HML components
  • Metabolomics and Lipidomics Contributions to Type 1 Diabetes Research F

    Metabolomics and Lipidomics Contributions to Type 1 Diabetes Research F

    CellR4 2020; 8: e2941 Metabolomics and lipidomics contributions to type 1 diabetes research F. Cesare Marincola Department of Chemical and Geological Sciences, University of Cagliari, University Campus, Monserrato, Cagliari, Italy Corresponding Author: F. Cesare Marincola, PhD; e-mail: [email protected] Keywords: Lipidomics, Metabolomics, Type 1 diabetes, creatic b-cells with consequent insulin deficiency. T1D. Type 2 diabetes (T2D) is the most common form of diabetes (about 90% of cases) and generally occurs ABSTRACT after 30-40 years of age5. T2D is characterized by a Metabolomics is a “omic” science with a focus on progressive loss of adequate b-cell insulin secretion the characterization of metabolome, that is the frequently on the background of insulin resistance. pool of low molecular weight (< 1.5 kDa) metab- Gestational diabetes is one of the most common olites involved in the metabolism of a biological pregnancy complications and usually disappears af- system. When the targets are lipids, metabolomics ter giving birth6. This condition occurs in about 7% is commonly referred to as lipidomics. Since the of pregnancies. The definition is valid regardless of metabolome composition is influenced by several the type of treatment (diet, physical exercise or insu- factors such as environment, disease, drugs, and lin) and the persistence of diabetes even after preg- genetics, metabolomics is extensively used in the nancy. Both World Health Organization (WHO) and biomedical research for the identification of met- American Diabetes Association (ADA) have identi- abolic signatures or novel biomarkers useful in fied an intermediate type of diabetes for individu- diagnosis, prediction, prognosis, and prevention als whose glucose levels do not meet the criteria for of disease.
  • Metabolomics in Situ 121

    Metabolomics in Situ 121

    TECHNOLOGY FEATURE Time to apply 119 Building pathways 120 Box 1: Metabolomics in situ 121 Metabolomics: from small molecules to big ideas Monya Baker The focus of metabolomic studies is shifting from cataloging chemical structures to finding biological stories. In 2004, when Alan Saghatelian wanted to know what reactions a particular enzyme catalyzed in vivo, he had to plow through a stack of paper two feet high. Standard in vitro techniques to uncover enzymes’ functions would have been much more straightfor- ward, but such studies work only when the right substrates are screened and even then might represent reactions that only occur in a test tube. To get a read on enzymatic activity in actual cells, Saghatelian, then a postdoc in Benjamin Cravatt’s laboratory at The Scripps Research Institute, developed an ‘untargeted metabolomics’ strategy to find previously unidentified substrates. Saghatelian lysed cells with and without the enzyme, ran the Diego San California, of University laboratory, Palsson Lewis, Nathan lysates through a mass spectrometer and Genomic, proteomic and metabolomic data can all be integrated using genome-scale metabolic compared the small molecule profiles found network reconstructions. in each sample. Nature America, Inc. All rights reserved. All rights Inc. America, Nature 1 This approach, which they termed dis- organism. The assumption was that a list Unlike genes, transcripts and proteins, covery metabolite profiling, yielded sub- of human metabolites could be as useful metabolites are not encoded in the genome. © 201 strates unlikely to have been found in vitro as a list of human genes. Such a list could They are also chemically diverse, consist- and led to the discovery of a new class of help researchers probe multiple pathways ing of carbohydrates, amino acids, lipids, mammalian lipids as substrates for an simultaneously, and collections of metabo- nucleotides and more.
  • Introduction to Metabolomics Research What Is

    Introduction to Metabolomics Research What Is

    06/29/2017 Introduction to metabolomics research Stephen Barnes, PhD University of Alabama at Birmingham [email protected] What is “Metabolomics”? • Metabolomics is like other types of –omics analysis (microarray, RNA‐Seq, proteomics, etc.) – Offers a “comprehensive” view of all detectable chemicals (not just metabolites) – Can be applied to body fluids • Plasma/sera, urine, saliva, tears, fecal water, etc. – Also to tissues • Liver, lung, heart, kidney, brain, eyes, etc. – And to single cells • Human, rodent, yeast, bacteria, etc. 1 06/29/2017 Defining who we are chemically • Are we “Living in the Promisedland” as per Willie Nelson’s song? • Does an understanding of the functions of human genes define the chemical make up of our body fluids and tissues? • How does metabolomics provide information on the circulating chemicals? • Are the detected chemicals metabolites produced by human enzymes? • So, what are we really exposed to? And does it make a difference? A great deal of emphasis is being placed on the importance of DNA sequencing This model works for congenital diseases Biliary atresia https://loveyabeckett.files.wordpress.com This has evolved into precision medicine and optimization of therapy http://personalizedmedicineproject.weebly.com/ 2 06/29/2017 Genes failed to meet expectations 80,000‐100,000 19,000‐ 20,000 2017 Pre‐1988 All but 400 Proteins have x 7 genes post‐translational found as modifications proteins In a biological system, what is the metabolome? G6P, lactate, pyruvate citrate, succinate, malate Intermediates aspartate,